Browse Tag

Nathalie Landry

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant. Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago, said: “Our Phase 1 results of the adjuvanted vaccine candidate were very encouraging and fully support further clinical evaluation.” Thomas Breuer, Chief Medical Officer GSK Vaccines said: “This is the first…

Read More »

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity.  Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial…